3 days ago
BMRN
AnalystsWhitney IjemWhitney Ijem's Stock Forecasts
AnalystsWhitney Ijem
Sectors:
Industries:
Analyst Ranking
Top 5%
#215 out of 5179 analysts
Average Return
+29.98%
Win Rate
54%59 out of 110
Risk vs Reward
Poor
Good
Whitney Ijem's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Arcturus Therapeutics Holdings IncARCT | +606.98% | $12.03 | $85.05 | 2020-02-06 - 2021-02-05 | Strong Buy |
Regulus Therapeutics IncRGLS | +482.48% | $1.37 | $7.98 | 2025-03-16 - 2025-04-30 | Strong Buy |
Palvella Therapeutics IncPVLA | +399.57% | $18.80 | $93.92 | 2025-02-25 - 2026-01-21 | Strong Buy |
Palvella Therapeutics IncPVLA | +394.32% | $19.00 | $93.92 | 2025-02-19 - 2026-01-21 | Strong Buy |
Palvella Therapeutics IncPVLA | +325.94% | $22.05 | $93.92 | 2025-05-15 - 2026-01-21 | Strong Buy |
Whitney Ijem Analyst Color
Get additional color on Whitney Ijem's coverage of popular stocks
a month ago
PVLA
a month ago
RYTM
a month ago
WVE
2 months ago
GUTS
2 months ago
PVLA
2 months ago
RYTM
3 months ago
PVLA
5 months ago
PVLA
5 months ago
TSHA
6 months ago
ALNY
6 months ago
RYTM
8 months ago
TSHA
8 months ago
TSHA
10 months ago
TNYA
a year ago
SRPT
a year ago
VERV
a year ago
RYTM
2 years ago
RARE
2 years ago
ARCT
2 years ago
RGLS
3 years ago
SGTX
Whitney Ijem's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biomarin Pharmaceutical IncBMRN | 9 | Strong Buy | $98.00 | +72.63% | Upgrades | 3 days ago |
Tenaya Therapeutics IncTNYA | 7 | Strong Buy | $5.00 | +598.32% | Maintains | a month ago |
Palvella Therapeutics IncPVLA | 8 | Strong Buy | $204.00 | +117.21% | Maintains | a month ago |
Rhythm Pharmaceuticals IncRYTM | 9 | Strong Buy | $141.00 | +33.08% | Maintains | a month ago |
Wave Life Sciences LtdWVE | 2 | Strong Buy | $40.00 | +186.94% | Maintains | a month ago |
Fractyl Health IncGUTS | 2 | Strong Buy | $8.00 | +332.43% | Maintains | 2 months ago |
Generation Bio CoGBIO | 3 | Strong Buy | $10.00 | +83.15% | Maintains | 5 months ago |
Passage Bio IncPASG | 7 | Strong Buy | $67.00 | +443.83% | Maintains | 5 months ago |
Taysha Gene Therapies IncTSHA | 11 | Strong Buy | $14.00 | +192.89% | Maintains | 5 months ago |
Ultragenyx Pharmaceutical IncRARE | 9 | Strong Buy | $128.00 | +462.64% | Maintains | 5 months ago |
Vertex Pharmaceuticals IncVRTX | 9 | Hold | $411.00 | -10.87% | Maintains | 6 months ago |
Alnylam Pharmaceuticals IncALNY | 9 | Strong Buy | $415.00 | +13.56% | Maintains | 6 months ago |
Rocket Pharmaceuticals IncRCKT | 9 | Strong Buy | $10.00 | +171.00% | Maintains | 6 months ago |
Verve Therapeutics IncVERV | 6 | Hold | $13.00 | +16.80% | Downgrades | 7 months ago |
Intellia Therapeutics IncNTLA | 6 | Strong Buy | $54.00 | +284.89% | Maintains | 8 months ago |
Arcturus Therapeutics Holdings IncARCT | 5 | Strong Buy | $66.00 | +807.84% | Maintains | 8 months ago |
Regulus Therapeutics IncRGLS | 6 | Hold | $11.00 | +34.80% | Downgrades | 9 months ago |
Sarepta Therapeutics IncSRPT | 1 | Strong Buy | $150.00 | N/A | Maintains | a year ago |
Sigilon Therapeutics IncSGTX | 2 | Strong Buy | $30.00 | N/A | Maintains | 3 years ago |
Neubase Therapeutics IncNBSE | 1 | Strong Buy | $260.00 | N/A | Initiates Coverage On | 6 years ago |
Karyopharm Therapeutics IncKPTI | 4 | Strong Buy | $240.00 | N/A | Upgrades | 6 years ago |
Acceleron Pharma IncXLRN | 2 | Strong Buy | N/A | N/A | Upgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.